[PCSK9 inhibitors and diabetes mellitus]

Abstract

Proproteinconvertase subtilisin kexin 9 (PCSK9) is a key regulator of low-density lipoprotein receptor (LDLR) expression. Anti-PCSK9 monoclonal antibody (MAb) therapy reduces LDL-cholesterol (LDL-C) by ~60 % and reduces also the risk of major adverse cardiovascular events. Mendelian randomisation studies showed that patients carrying loss-of-function PCSK9 genetic variants display lower LDL-C and have an increased risk of developing type 2 diabetes (T2DM). Randomized controlled trials with anti-PCSK9 MAbs however showed no effect on the risk. A possible explanation of the discrepancy is that the deficiency of locally but not circulating PCSK9 is responsible for increased LDLR expression in pancreatic islets, which results in cholesterol accumulation and B-cell dysfunction. Thus PCSK9 lowering therapy with MAb targeting mainly circulating PCSK9 might have a limited impact on LDLR expression in pancreatic cells and on the risk of T2DM. Long-term clinical trials are however needed to confirm it. Key words: diabetes mellitus - LDL receptor - PCSK9.

Keywords: diabetes mellitus - LDL receptor - PCSK9.